May 10, 2018 / 5:11 AM / 15 days ago

BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib

May 10 (Reuters) - Exelixis Inc:

* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER

* STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL VERSUS REGORAFENIB

* GENENTECH INFORMED CO COMBINATION OF ATEZOLIZUMAB AND COBIMETINIB DID NOT DELIVER IMPROVEMENT IN OVERALL SURVIVAL VERSUS REGORAFENIB

* GENENTECH WILL FURTHER EXAMINE RESULTS FROM IMBLAZE370 AND PLANS TO PRESENT DATA AT AN UPCOMING MEDICAL MEETING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below